22 October 2017
News and Views
Links and Services
A study in this month's Inflammatory Bowel Disease reviews the potential risk of anti–TNF-α antibody use in the perioperative period.
Biologic therapy with anti–tumor necrosis factor (TNF)-α antibody medications has become par
Email this page to a colleague
GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors